Navigation Links
BioRealm to Develop Universal Genetic Screening Tool for Tobacco Addiction and Treatment
Date:6/20/2012

Los Angeles, CA (PRWEB) June 20, 2012

BioRealm, LLC announced today that it has been awarded a Small Business Innovative Research contract by the U.S. National Institute on Drug Abuse (NIDA) to develop a universal genetic screening tool for tobacco addiction and treatment approaches. BioRealm’s “Smokescreen” product will integrate recent advances in tobacco addiction research and allow researchers to study thousands of an individual’s genetic variants related to tobacco dependence and treatment response.

According to the Centers for Disease Control and Prevention (CDC), smoking is the leading cause of preventable disease in the U.S., resulting in $96 billion in annual health care costs. Despite the availability of numerous smoking cessation products and treatments, effectiveness varies greatly and people often relapse. Studies have shown that genetic variation plays a significant role in nicotine dependence, including the ability to quit smoking and response to nicotine replacement therapy and medication. However, the genetics of tobacco addiction are not yet fully understood.

Addiction researchers have so far been limited by the small number of participants in clinical trials, and the lack of a validated genetic screening tool and centralized database for storing results. “The Smokescreen aims to solve these problems by featuring a uniform set of genetic variants, with genotyping results automatically stored and accessible via a secure cloud-based application”, stated Christopher Edlund, Bioinformatics Principal at BioRealm. “The ability to seamlessly share and compare data across multiple studies will enable researchers and clinicians to more effectively investigate tobacco addiction”.

Scientists at BioRealm envision the Smokescreen to be the standard genetic test used by clinical trials for smoking cessation. “The Smokescreen will be an invaluable resource for developing personalized smoking cessation treatments and ultimately reducing tobacco use in the U.S.”, said BioRealm co-founder Dr. James Baurley.

Additional information related to the Smokescreen product can be found at http://www.biorealmresearch.com/smokescreen.

About BioRealm

Founded in 2006, BioRealm develops solutions for genetic research and the biomedical industry.

Source: BioRealm, LLC

Read the full story at http://www.prweb.com/releases/2012/6/prweb9621970.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NASA develops super-black material that absorbs light across multiple wavelength bands
2. Gated STED -- developing the next generation of super-resolution microscopes
3. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
4. Multidisciplinary team of researchers develop world’s lightest material
5. UCLA team develops highly efficient method for creating flexible, transparent electrodes
6. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
7. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
10. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
11. Researchers develop one of the worlds smallest electronic circuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Renova™ Therapeutics, a biotechnology ... failure and type 2 diabetes, announced that it ... adeno-associated virus (AAV) vector developed in the laboratory ... at Stanford University. The company plans to use ... therapy product pipeline. "Early research ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review and report looks at ... focus on the economic effects in countries that are major global commodity exporters and ... the resultant risk of low level presence (LLP) puts large volumes of trade worth ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
Breaking Biology Technology:
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):